ARTICLE | Clinical News
BTI320: Ph II SG01 data
December 27, 2016 5:14 PM UTC
Top-line data from the double-blind, Chinese Phase II SG01 trial in 60 high-risk prediabetes patients who are otherwise healthy showed that thrice-daily 4 and 8 g oral doses of BTI320 for 16 weeks wer...
BCIQ Company Profiles
BCIQ Target Profiles